Publicacions en què col·labora amb Jesús María Prieto Valtueña (204)

2020

  1. Brain ventricular enlargement in human and murine acute intermittent porphyria

    Human molecular genetics, Vol. 29, Núm. 19, pp. 3211-3223

  2. Identifying differentially expressed micrornas, target genes, and key pathways deregulated in patients with liver diseases

    International Journal of Molecular Sciences, Vol. 21, Núm. 19, pp. 1-16

2019

  1. La clínica y el laboratorio: interpretación de análisis y pruebas funcionales, exploración de los síndromes, cuadro biológico de las enfermedades

    Elsevier

  2. Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses

    Molecular Therapy, Vol. 27, Núm. 11, pp. 1892-1905

  3. The cirrhotic liver is depleted of docosahexaenoic acid (DHA), a key modulator of NF-κB and TGFβ pathways in hepatic stellate cells

    Cell Death and Disease, Vol. 10, Núm. 1

2017

  1. Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: Development of an FGF19-based chimeric molecule to promote fatty liver regeneration

    Gut, Vol. 66, Núm. 10, pp. 1818-1828

  2. Phase 1–2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow–derived endothelial progenitor cells

    Translational Research, Vol. 188, pp. 80-91.e2

  3. X-box Binding Protein 1 Regulates Unfolded Protein, Acute-Phase, and DNA Damage Responses During Regeneration of Mouse Liver

    Gastroenterology, Vol. 152, Núm. 5, pp. 1203-1216.e15

2016

  1. Factors related to increased resting energy expenditure in men with liver cirrhosis

    European Journal of Gastroenterology and Hepatology, Vol. 28, Núm. 2, pp. 139-145

  2. Insulin-like growth factor I (IGF-I) expressed from an AAV1 vector leads to a complete reversion of liver cirrhosis in rats

    PLoS ONE, Vol. 11, Núm. 9

  3. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria

    Journal of Hepatology, Vol. 65, Núm. 4, pp. 776-783

  4. Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression

    Oncogene, Vol. 35, Núm. 36, pp. 4719-4729

  5. Transient expression of transgenic IL-12 in mouse liver triggers unremitting inflammation mimicking human autoimmune hepatitis

    Journal of Immunology, Vol. 197, Núm. 6, pp. 2145-2156

2015

  1. Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection

    Molecular Therapy - Methods and Clinical Development, Vol. 2, pp. 15006

  2. La clínica y el laboratorio: interpretación de análisis y pruebas funcionales, exploración de los síndromes, cuadro biológico de las enfermedades

    Elsevier Masson

  3. Matrix Metalloproteinase 10 Contributes To Hepatocarcinogenesis in a Novel Crosstalk With the Stromal Derived Factor 1/C-X-C Chemokine Receptor 4 Axis

    Hepatology, Vol. 62, Núm. 1, pp. 166-178

2014

  1. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation

    Journal of Hepatology, Vol. 60, Núm. 5, pp. 1017-1025

  2. Comparación de las sondas M y XL para estimar la rigidez hepática por medio de elastografía de transición

    Gastroenterologia y Hepatologia, Vol. 37, Núm. 4, pp. 233-239

  3. Matrix metalloproteinase-10 expression is induced during hepatic injury and plays a fundamental role in liver tissue repair

    Liver International, Vol. 34, Núm. 7

  4. Splicing regulator SLU7 is essential for maintaining liver homeostasis

    Journal of Clinical Investigation, Vol. 124, Núm. 7, pp. 2909-2920